[go: up one dir, main page]

WO2020038293A1 - Procédé de traitement d'une valve biologique à l'aide d'une combinaison de réticulation enzymatique et de polyphénol de thé - Google Patents

Procédé de traitement d'une valve biologique à l'aide d'une combinaison de réticulation enzymatique et de polyphénol de thé Download PDF

Info

Publication number
WO2020038293A1
WO2020038293A1 PCT/CN2019/101014 CN2019101014W WO2020038293A1 WO 2020038293 A1 WO2020038293 A1 WO 2020038293A1 CN 2019101014 W CN2019101014 W CN 2019101014W WO 2020038293 A1 WO2020038293 A1 WO 2020038293A1
Authority
WO
WIPO (PCT)
Prior art keywords
linking
biological
tea polyphenols
combination
valves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/101014
Other languages
English (en)
Chinese (zh)
Inventor
王云兵
雷洋
訾振军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan University
Venus Medtech Hangzhou Inc
Original Assignee
Sichuan University
Venus Medtech Hangzhou Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan University, Venus Medtech Hangzhou Inc filed Critical Sichuan University
Publication of WO2020038293A1 publication Critical patent/WO2020038293A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Definitions

  • the invention relates to the technical field of biomedical materials and medical devices, in particular to a method for treating a biological valve using a combination of enzyme cross-linking and tea polyphenols and a biological material thereof.
  • Heart valve disease is a common valvular disease. Anatomically manifested as narrowed blood passages or valvular insufficiency.
  • Heart valve disease Treatment of heart valve disease includes thoracotomy and percutaneous heart valve replacement.
  • Thoracic surgery is very traumatic, high risk, slow recovery, and requires extracorporeal circulation support, which is unacceptable to many patients.
  • Percutaneous heart valve replacement surgery has become the main trend of future valve surgery because it has less trauma to patients and low risk.
  • Biological heart valves are a class of biomedical materials used to replace heart valves in humans. Biological heart valves are generally prepared by cross-linking glutaraldehyde from porcine pericardium and bovine pericardium.
  • Glutaraldehyde cross-linking treatment has the characteristics of simple operation, low cost and high degree of collagen cross-linking, and is currently the industry's first choice for chemical cross-linking of biological heart valves.
  • glutaraldehyde cross-linked biological heart valves have problems of easy degradation and calcification, resulting in biological heart valves having a useful life of only about 10 years.
  • Glutaraldehyde can achieve stable cross-linking of collagen, but it cannot cross-link elastin, resulting in certain technical limitations.
  • the purpose of the present invention is to provide a method for treating biological valves by using a combination of enzyme cross-linking and tea polyphenols to solve the above-mentioned shortcomings of the prior art, which can effectively improve the structural stability and anti-calcification of biological materials such as biological heart valves. Performance, potentially extending its useful life.
  • a method for treating biological valves by using a combination of enzyme cross-linking and tea polyphenols specifically includes the following steps:
  • step S3 The biomaterials washed in step S2 are then modified with hydroxyphenylpropionic acid.
  • An aqueous solution having a molar concentration of hydroxyphenylpropionic acid of 1 mM to 1M is used, and a molar solution of the carbodiimide / N-hydroxysuccinimide is used. Degree is 0.01-1M;
  • step S4 The tea polyphenols are soaked in the biological material processed in step S3, and the mass concentration of the tea polyphenols used is 0.1% -10%;
  • step S5. Perform horseradish peroxidase / hydrogen peroxide-induced enzyme cross-linking on the biological material treated in step S4.
  • the mass concentration of horseradish peroxidase used is 0.1% -10%, and the mass of hydrogen peroxide used The concentration is 0.1% -10%;
  • step S1 fresh biological materials, such as pericardial tissue of pigs or cattle, are collected and stored in a low-temperature and humid state at 4 degrees Celsius.
  • step S2 the pericardial tissue is washed with distilled water under gentle vibrations and fluid pressure under oscillating conditions to remove adhered non-pericardial and non-collagenous tissues.
  • the washing achieves effective decellularization of the pericardial tissue through osmotic shock. And, preferably, the washing is continued until there is no visible adherent non-pericardial or non-collagenous tissue, and preferably, it is washed with distilled water under a shaking condition of 100 RPM at 4 degrees Celsius for 2 hours.
  • step S3 the washed biological material is modified with hydroxyphenylpropionic acid, and an aqueous solution having a molar concentration of hydroxyphenylpropionic acid of 1mM-1M is used.
  • This step needs to ensure that hydroxyphenylpropionic acid reaches a near-saturated physical penetration. Thereby, as much as possible is introduced.
  • step S4 the treated biomaterial is soaked with tea polyphenols, and the mass concentration of the used tea polyphenols is 0.1% -10%.
  • the tea polyphenols are adsorbed on the hydrophobic section of the elastin fiber by hydrogen bonding, thereby improving Structural stability of elastin.
  • step S5 the treated biological material is subjected to horseradish peroxidase / hydrogen peroxide-induced enzyme cross-linking, and the mass concentration of horseradish peroxidase used is 0.1% -10%.
  • the mass concentration of hydrogen oxide is 0.1% -10%.
  • Hydrogen peroxide is an oxidant. Under the action of oxidant, horseradish peroxidase can catalyze the phenolic hydroxyl group to achieve chemical crosslinking.
  • step S6 washing with distilled water is performed. This washing step will remove unreacted tea polyphenols, horseradish peroxidase, and hydrogen peroxide.
  • the beneficial effect of the present invention is that the method provided by the present invention can improve the structural stability and anti-calcification performance of the biological material, and potentially prolong its service life.
  • FIG. 1 is a specific flowchart of a prepared biological heart valve.
  • Figure 2 is a schematic diagram of the chemical principle of p-hydroxyphenylpropionic acid modified pericardium and horseradish peroxidase / catalase cross-linking.
  • FIG. 3 is the percentage of weight loss of enzyme degradation obtained by using Example 1.
  • FIG. FP Fresh pig pericardium.
  • GLUT glutaraldehyde treatment group.
  • EDC carbodiimide treatment group.
  • HPA / EDC / EGCG p-hydroxyphenylpropionic acid, carbodiimide, gallocatechin gallate enzyme cross-linked treatment group.
  • FIG. 4 is a result of quantitative detection of elastin obtained in Example 1.
  • FIG. GLUT glutaraldehyde treatment group.
  • EDC carbodiimide treatment group.
  • HPA / EDC / EGCG p-hydroxyphenylpropionic acid, carbodiimide, gallocatechin gallate enzyme cross-linked treatment group.
  • FIG. 5 is a test result of the amount of calcium implanted subcutaneously in the rat obtained in Example 1.
  • FIG. GLUT glutaraldehyde treatment group.
  • EDC carbodiimide treatment group.
  • HPA / EDC / EGCG p-hydroxyphenylpropionic acid, carbodiimide, gallocatechin gallate enzyme cross-linked treatment group.
  • the freshly collected pig pericardium is washed with distilled water for 2 hours under a shaking condition of 100 degrees RPM at 4 degrees Celsius. Then immerse in 50 mM hydroxyphenylpropanoic acid in water at room temperature for 4 hours. It was then soaked at room temperature for 24 hours with 10 mM carbodiimide and 10 mMN-hydroxysuccinimide. It was then soaked with 1% epigallocatechin gallate for 24 hours. It was then immersed in 1% horseradish peroxidase and 1% hydrogen peroxide at 150 RPM at 37 ° C for 24 hours.
  • the freshly collected pig pericardium is washed with distilled water for 2 hours under a shaking condition of 100 degrees RPM at 4 degrees Celsius. Then immerse in 100 mM hydroxyphenylpropanoic acid in water at room temperature for 4 hours. It was then soaked at room temperature for 24 hours with 10 mM carbodiimide and 10 mMN-hydroxysuccinimide. It was then soaked with 1% epigallocatechin gallate for 24 hours. Then it was immersed in 1% horseradish peroxidase and 1% hydrogen peroxide at 37 ° C and 150 RPM for 24 hours.
  • freshly collected pig pericardium is washed with distilled water under a shaking condition of 4 ° C and 100 RPM for 2 hours. Then immerse in 100 mM hydroxyphenylpropanoic acid in water at room temperature for 4 hours. It was then soaked at room temperature for 24 hours with 10 mM carbodiimide and 10 mMN-hydroxysuccinimide. It was then soaked with 1% epigallocatechin gallate for 24 hours. Then immerse in 5% horseradish peroxidase and 5% hydrogen peroxide at 37 ° C and 150 RPM for 24 hours.
  • pericardial (FP) group fresh pericardial (FP) group.
  • GLUT Glutaraldehyde
  • EDC carbodiimide
  • the glutaraldehyde (GLUT) treatment group the pericardium was immersed in 0.625% glutaraldehyde for 24 hours.
  • the carbodiimide (EDC) treatment group was immersed in 10 mM carbodiimide and 10 mM N-hydroxysuccinimide for 24 hours.
  • the beneficial effect of the present invention is that the method provided by the present invention can improve the stability and anti-calcification performance of the elastin of the biological material, potentially extending its service life.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne un procédé de traitement d'une valve biologique à l'aide de la combinaison de réticulation enzymatique et d'un polyphénol de thé. Le procédé comprend : la modification du péricarde porcin ou bovin à l'aide d'acide hydroxyphénylpropionique, puis le trempage avec un polyphénol de thé, puis l'initiation d'une réticulation enzymatique dans des conditions de peroxydase de raifort et de peroxyde d'hydrogène. L'acide hydroxyphénylpropionique introduit un groupe hydroxyle phénolique dans le péricarde, et le polyphénol de thé exogène fournit un groupe hydroxyle phénolique supplémentaire. La peroxydase de raifort et le peroxyde d'hydrogène mettent en oeuvre la réticulation chimique du groupe hydroxyle phénolique. Le procédé selon la présente invention peut améliorer la stabilité structurelle et les performances anticalcification d'un biomatériau et potentiellement prolonger la durée de vie du biomatériau.
PCT/CN2019/101014 2018-08-20 2019-08-16 Procédé de traitement d'une valve biologique à l'aide d'une combinaison de réticulation enzymatique et de polyphénol de thé Ceased WO2020038293A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810949307.4 2018-08-20
CN201810949307.4A CN110841110B (zh) 2018-08-20 2018-08-20 一种采用酶交联和茶多酚组合联用处理生物瓣膜的方法

Publications (1)

Publication Number Publication Date
WO2020038293A1 true WO2020038293A1 (fr) 2020-02-27

Family

ID=69592270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/101014 Ceased WO2020038293A1 (fr) 2018-08-20 2019-08-16 Procédé de traitement d'une valve biologique à l'aide d'une combinaison de réticulation enzymatique et de polyphénol de thé

Country Status (2)

Country Link
CN (1) CN110841110B (fr)
WO (1) WO2020038293A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952513B (zh) * 2021-11-29 2022-11-15 四川大学华西医院 一种抗衰败人工生物瓣膜及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1775304A (zh) * 2005-11-30 2006-05-24 中国科学院上海硅酸盐研究所 具有生物活性的人工生物瓣瓣膜的制备方法
CN101224313A (zh) * 2008-02-04 2008-07-23 中国科学院上海硅酸盐研究所 采用槲皮素交联制备人工生物心脏瓣膜材料的方法
CN101690829A (zh) * 2009-08-31 2010-04-07 中国科学院上海硅酸盐研究所 一种可再细胞化的生物瓣瓣膜材料的制备方法
CN105326581A (zh) * 2015-09-29 2016-02-17 中国科学院金属研究所 一种制备聚乙二醇-蛋白质纤维复合人工心脏瓣膜的方法
US20160303289A1 (en) * 2013-07-31 2016-10-20 Biotronik Ag Method for preparing biological tissue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040153145A1 (en) * 2002-11-26 2004-08-05 Clemson University Fixation method for bioprostheses
CN102114270B (zh) * 2011-02-22 2013-08-07 上海微创医疗器械（集团）有限公司 一种梯度交联及修饰型耐久性人工生物瓣及其制备方法
CN102114269B (zh) * 2011-02-22 2013-12-11 上海微创医疗器械（集团）有限公司 一种异氰基封端型防钙化人工生物瓣及其制备方法
US9283241B2 (en) * 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
CN103224916A (zh) * 2013-05-10 2013-07-31 南开大学 人工辣根过氧化物酶及其催化酚类物质聚合的方法
CN103397075A (zh) * 2013-06-10 2013-11-20 湖南科技学院 一种辣根过氧化物酶的新底物体系及其配制方法
CN104857550B (zh) * 2015-05-29 2017-03-15 南京工业大学 一种ε‑聚赖氨酸‑对羟基苯丙酸抗菌水凝胶敷料及其制备方法
CN105601701A (zh) * 2016-01-21 2016-05-25 中国农业大学 一种蛋白质-多酚共价复合物及其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1775304A (zh) * 2005-11-30 2006-05-24 中国科学院上海硅酸盐研究所 具有生物活性的人工生物瓣瓣膜的制备方法
CN101224313A (zh) * 2008-02-04 2008-07-23 中国科学院上海硅酸盐研究所 采用槲皮素交联制备人工生物心脏瓣膜材料的方法
CN101690829A (zh) * 2009-08-31 2010-04-07 中国科学院上海硅酸盐研究所 一种可再细胞化的生物瓣瓣膜材料的制备方法
US20160303289A1 (en) * 2013-07-31 2016-10-20 Biotronik Ag Method for preparing biological tissue
CN105326581A (zh) * 2015-09-29 2016-02-17 中国科学院金属研究所 一种制备聚乙二醇-蛋白质纤维复合人工心脏瓣膜的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANG, LEI ET AL.: "EGCG and Enzymatic Cross-Linking Combined Treatments for Improving Elastin Stability and Reducing Calcification in Bioprosthetic Heart Valves", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B: APPLIED BIOMATERIALS ., vol. 107, no. 5, 29 September 2018 (2018-09-29), pages 1551 - 1559, XP055687916, ISSN: 1552-4973, DOI: 10.1002/jbm.b.34247 *

Also Published As

Publication number Publication date
CN110841110A (zh) 2020-02-28
CN110841110B (zh) 2021-03-12

Similar Documents

Publication Publication Date Title
CA2666485C (fr) Tissu biologique pour implantation chirurgicale
EP3854425B1 (fr) Valvule cardiaque biologique séchée préchargeable et procédé de préparation correspondant
US12102733B2 (en) Pre-loadable biological heart valve capable of rapid rehydration and preparation method thereof
JP4555570B2 (ja) 移植後の石灰化を軽減する生物補綴組織の処理
WO2021239080A1 (fr) Valve cardiaque biologique ayant à la fois des propriétés d'anticoagulation et d'anti-calcification, et sa méthode de préparation
WO2018167536A1 (fr) Matériau implantable et procédé de conservation
CN108785747A (zh) 一种提高生物材料抗钙化性能的处理方法及其生物材料
CN110152066A (zh) 一种提高生物材料结构稳定性能的方法及其生物材料
WO2020057414A1 (fr) Valve cardiaque biologique sèche capable d'absorber rapidement de l'eau et de s'aplatir, et son procédé de préparation
CN111166938B (zh) 一种非戊二醛可预装干燥生物瓣膜材料及制备方法和应用
CN109833118B (zh) 一种采用交联处理提高生物瓣膜稳定性的方法
CN112915260B (zh) 一种非戊二醛交联生物材料及其制备方法
CN111514375A (zh) 一种抗钙化生物瓣膜材料及其制备方法
CN112236175A (zh) 制备用于外科手术植入的生物组织的方法
WO2022134858A1 (fr) Procédé de traitement de tissu prothétique biologique, et valvule cardiaque prothétique biologique
CN109833518B (zh) 一种生物心脏瓣膜促进内皮化的方法
WO2020038293A1 (fr) Procédé de traitement d'une valve biologique à l'aide d'une combinaison de réticulation enzymatique et de polyphénol de thé
CN109833517B (zh) 一种提高生物瓣膜弹性蛋白稳定性的交联处理方法
CN109820624B (zh) 一种采用光交联处理生物瓣膜的方法
WO2022143700A1 (fr) Matériau biologique réticulé déshydraté résistant au pliage, procédé de préparation associé et application associée
CN110917398A (zh) 生物材料的抗氧化方法及生物材料
CN109836507B (zh) 一种提高生物心脏瓣膜糖胺多糖稳定性的方法
CN115350332A (zh) 抗钙化生物瓣膜材料的制备方法及抗钙化生物瓣膜材料
RU2809478C2 (ru) Способ предотвращения разложения и дегенерации ткани, используемой в биопротезах
RU2827554C2 (ru) Способ получения биологической ткани для хирургической имплантации

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19852416

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19852416

Country of ref document: EP

Kind code of ref document: A1